Baxter to establish $200M venture arm

Baxter International is looking to invest in early-stage companies whose offerings complement its existing portfolio of medical products. It will invest up to $200 million in such companies through Baxter Ventures. "As the company's internal capabilities have advanced our late-stage pipeline, we have the capacity to further accelerate the early-stage development of essential therapies," Robert Parkinson, Jr., chairman and CEO of Baxter, said in a statement.  Baxter release | Story

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.